This study investigates the use of a novel liquid biopsy test to detect recurrence in individuals who have been treated for early-stage solid tumors. The purpose of this study is to observe the relationship between test results and clinical outcomes.
The study evaluates the effectiveness of the liquid biopsy test in a healthcare setting. It explores the test's potential value in monitoring patients while considering cost factors.
- Who can participate: Adults over 18 years who have been treated for early-stage solid tumors with curative intent and are undergoing regular follow-up for cancer recurrence can participate. Participants must consent to provide blood samples and share clinical data.
- Study details: Participants will provide blood samples at enrollment and during follow-up visits for up to 5 years. The study involves sharing de-identified clinical data with researchers. A placebo is not involved in this study.
- Study timelines: The study will last up to 5 years.
How understandable was the trial content above?
Hard to understand
Easy to understand